Autres langues Innovent Biologics, Inc.

Actions

1801

KYG4818G1010

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:08:16 24/04/2024			Varia. 5j.	Varia. 1 janv.
38,15 ^HKD	+5,53 %		+11,22 %	-10,76 %

17/04	Innovent nomme le Dr Nageatte Ibrahim au poste de Chief Medical Officer en oncologie	CI
02/04	La demande de traitement du cancer de l'endomètre de Hutchmed acceptée pour examen	AN

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer	17/04
Innovent Appoints Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer	17/04
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status	03/04
Hutchmed endometrial cancer treatment application accepted for review	02/04
Hutchmed, Innovent Biologics Say Chinese Regulator Accepts Application for Endometrial Cancer Drug Combination	02/04
HSBC in special payout on Canada sale; Astra FDA win	02/04
Innovent Biologics New Cancer Drug Gets NDA from Chinese Authority	02/04
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status	02/04
Innovent Biologics, Inc. Announces the National Medical Products Administration Accepts the New Drug Application	02/04
Innovent Biologics' Loss Narrows in 2023 as Revenue Grows	21/03
Innovent Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03
Innovent Biologics, Inc. Releases the Results of Two Clinical Studies of Ibi311 (An Anti-IGF-1R Monoclonal Antibody) in Oral Presentations At the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024	07/03
Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer	06/03
China Accepts Innovent's Second Drug Application for Lung Cancer Treatment; Shares Slide 6%	05/03
Anheart Therapeutics and Innovent Announces China?s NMPA Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of Ros1-Positive Lung Cancer	05/03
Innovent Biologics' Phase 3 Trial for Thyroid Eye Disease Treatment Meets Primary Endpoints	20/02
Innovent Biologics, Inc. Announces the Phase 3 Clinical Study of Ibi311 Met the Primary Endpoint in Treating Thyroid Eye Disease	20/02
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials	16/02
Innovent Biologics, Inc. Announces Appointment of Shun Lu as Independent Non-Executive Director and A Member of the Strategy Committee	09/02
Innovent Biologics’ New Drug Application for Weight Management Drug Accepted by Chinese Regulator	07/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Innovent Biologics, Inc.

Actions

1801

KYG4818G1010

Autres langues

Filtres